NCT05824481View on ClinicalTrials.gov

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions
Endometrial CancerEndometrial Adenocarcinoma
Interventions
DRUG

Cadonilimab

Injectable solution

DRUG

Lenvatinib

Capsule

Trial Locations (1)

510060

Sun Yat-sen University Cancer Cetntre, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT05824481 - Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer | Biotech Hunter | Biotech Hunter